Structure Therapeutics Stock Explodes As Much-Awaited Experimental Oral Drug Trial Shows Weight Loss Of 16%

The stock's rise comes as the company reported significant weight loss results from its investigational oral drug, aleniglipron, which is designed for treating obesity, while broader markets experienced mixed movements.